Medication classes
Investigational treatment articles covering pipeline drugs, experimental therapies, early trial results, and emerging IBD science. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
14 articles
This trial focuses on fibrostenosing Crohn’s disease, a form of IBD where strictures can block the intestine; a successful drug could offer a medical option to improve endoscopic passability and reduce need for...
This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.
Patients with fibrostenosing Crohn’s disease face progressive strictures and limited targeted treatments; data from STENOVA’s OLE and the planned NOV‑ERA trial could advance therapies that target both inflammation and...
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
This report describes open‑label extension data for ontunisertib, an investigational oral drug being tested specifically for fibrostenosing Crohn’s disease.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...
Cure8 could only read part of this source from rttnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib.
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
Patients with fibrostenosing Crohn’s disease have limited treatment options for the fibrotic strictures that can lead to procedures and surgery. These OLE findings suggest ontunisertib may be safe long-term and could...
Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
This trial targets fibrotic narrowings (strictures) in Crohn’s disease — a common complication without approved drug treatments — so positive results could change care options and reduce the need for surgery.
People with Crohn's disease often develop intestinal fibrosis and strictures that current drugs don't reverse; a growing drug pipeline aiming at anti‑fibrotic therapies could change future treatment options.
